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Cirrhosis is characterized 
by a dynamic, precarious
hemostatic balance
Platelets play an important role in
coagulation balance of cirrhotic patients
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Cirrhotic patients are at increased risk of bleeding, particularly 
gastrointestinal bleeding, as a consequence of portal hypertension 
and/or coagulopathy attributed to liver synthetic dysfunction. 
Paradoxically, they are also at risk of thrombosis, predominantly in the 
splanchnic circulation, especially when platelet counts are increased 
by transfusion or drug therapy [1,2]. A major problem in clinical practice 
is the inadequacy of coagulation tests, which do not predict bleeding or 
thrombotic events, but may result in the inappropriate administration of 
therapies (e.g., plasma transfusions prior to procedures). Additionally, 
these tests cannot provide information on the dynamic interaction 
between the coagulation and anticoagulation pathways. Evidence 
is mounting to highlight the central role of the platelet, of which the 
quantitative and qualitative properties may determine the dynamic 
hemostatic forces in cirrhosis.
   Cirrhotic thrombocytopenia and platelet dysfunction are multifactorial 
with many simultaneous contributions [1]. Portal hypertension 
leads to splenic pooling, sequestering platelets from the circulation. 
Portosystemic shunting and gut barrier disruption result in 
endotoxaemia with systemic immune activation, antiplatelet antibody 
production, aberrant fibronolysis, and activation of coagulation with 
platelet consumption [1]. Cirrhosis and decreased functional liver mass 
result in lower thrombopoetin levels and platelet underproduction.
   There are 3 phases of clotting in which platelets play a crucial role: 
primary hemostasis (platelet-vessel wall interactions), coagulation 
(thrombin generation), and fibrinolysis (clot dissolution). In general, 
thrombocytopenia, with a reduced number of functional platelets, 
appears to impact blood coagulation the most, by limiting thrombin 
generation. Despite prolonged prothrombin times, thrombin generation 
appears to be maintained in cirrhosis as a result of protein C 
deficiency [3]. Using techniques that assess protein C activity, cirrhotic 
plasma appears hypercoagulable until severe thrombocytopenia 
occurs. In vitro studies of platelet-rich plasma from cirrhotic patients 
support normal thrombin generation if platelets are at least 60,000 
[4]. Interestingly, disturbing the new procoagulant and anticoagulant 
balance in cirrhosis, by raising platelet counts using pharmacological 
therapy (e.g., eltrombopag), increases the risk of thrombosis, mainly 
in the portal circulation [2].
   Qualitative platelet defects in cirrhosis are dynamic and reflect the 
patient’s overall health. They manifest in each step of the multiphasic 
platelet-vessel wall interaction: adhesion, aggregation, and activation.
   Adhesion: compared to healthy patients, cirrhotic platelet adherence 
to the subendothelium of injured vessels is defective, akin to that 
observed in uremia [5]. A weak but significant correlation exists 
between the platelet count and bleeding time [6]. The correlation is 
weak as platelet defects are partially compensated by a concomitant 
increase in the adhesive protein von Willebrand factor [7].
   Aggregation: in response to any number of stimuli – ADP, thrombin, 
collagen, epinephrine, or ristocetin – the degree of platelet aggregation 
is significantly less in cirrhosis compared to healthy controls [8].
   Activation: the cirrhotic platelet is said to be ‘exhausted,’ exhibiting 
reduced transmembrane signaling and a progressive inability to 
activate in response to appropriate stimuli. Many reasons account 
for this observation: (i) cirrhotic platelets have a ‘storage pool defect’ 
whereby dense granule concentrations of prothrombotic signaling 
molecules (e.g., platelet factor 4, beta-thromboglobulin, and serotonin) 
are abnormally low; (ii) cirrhotic platelets secrete disproportionately 
high levels of ATP. Excess extracellular ATP antagonizes ADP-induced 
activation of receptor P2Y12 (i.e., clopidogrel’s target) and desensitizes 
P2Y1 resulting in lower intraplatelet ionized calcium levels [9,10]; (iii) 
there is an intraplatelet accumulation of inhibitory messengers (cyclic 
nucleotides), sharply limiting phospholipase activity, resulting in lower 
concentrations of inositol phosphate and calcium [11]. The end-result 
is platelets that produce less thromboxane and serotonin, precipitating 
cascading defects in platelet aggregation [9].
  Each qualitative platelet defect is progressive with increasing 
Child’s class. This allows us to generate hypotheses regarding 
underlying mechanisms. Diminished intrinsic liver function, however, 
will not suffice, as features of cirrhotic coagulopathy can be seen in 
non-cirrhotic patients with portal vein thrombosis or other causes of 
extrahepatic portal hypertension. Qualitative platelet defects are likely 
reflective of increased bloodstream endotoxin concentration vis-à-
vis portosystemic shunting and gut barrier disruption [1,12]. Platelet-
derived microparticles, in turn, are increased in cirrhosis as a function 
of systemic inflammation. Microparticles have a known procoagulant 
effect and may play an important role in the relative hypercoagulability 
of early cirrhosis [12].
   The literature offers a number of strategies that may reduce endotoxin 
load or the effects of the consequent inflammation: gut decontamination 
(e.g., rifaximin), treatment of intrahepatic endothelial dysfunction 
(e.g., antioxidants) or prevention of gut bacterial translocation (e.g., 
beta blockers, anticoagulants). A recent trial of enoxaparin in highly 
selected non-thrombocytopenic cirrhotics has shown dramatic 
reductions in the frequency of hepatic decompensation. This landmark 
study may reverse dogma, should further investigation confirm that 
anticoagulation reduces bacterial translocation and microthrombi 
in the hepatic circulation, improving liver function in this selected 
population [13]. It is yet to be determined if this is a viable therapeutic 
option in more advanced liver disease without promoting bleeding.
   In summary, in cirrhosis, the normal homeostatic reserve capacity 
to control bleeding and thrombosis events is lost, with the predilection 
toward bleeding or thrombosis dependent on the individual and the 
precipitant. Evidence is emerging on the central role of the platelet in 
this process.
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